



*IPW*

Docket No.: 27866/39702A  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Lynne C. Weaver et al.

Application No.: 10/578,562

Confirmation No.: 7896

Filed: May 8, 2006

Art Unit: Not Yet Assigned

For: METHODS OF TREATING CHRONIC PAIN  
USING COMPOSITIONS THAT  
SPECIFICALLY BIND CD11D (ALPHA-D)  
INTEGRIN

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other

material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 27866/39702A. A copy of this paper is enclosed.

Dated: December 28, 2006

Respectfully submitted,

By   
Katherine L. Neville

Registration No.: 53,379  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Agent for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/578,562-Conf. #7896	
			Filing Date	May 8, 2006	
			First Named Inventor	Lynne C. Weaver	
			Art Unit	Not Yet Assigned 1649	
			Examiner Name	K. Ballard	
Sheet	1	of	3	Attorney Docket Number	27866/39702A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US-4,289,872	09-15-1981	Denkewalter et al.	
	A2	US-4,946,778	08-07-1990	Ladner et al.	
	A3	US-5,229,490	07-20-1993	Tam	
	A4	US-5,585,089	12-17-1996	Queen et al.	
	A5	US-5,643,759	07-01-1997	Pfeundschuh et al.	
	A6	US-5,693,762	12-02-1997	Queen et al.	
	A7	US-5,798,229	08-25-1998	Strittmatter et al.	
	A8	US-6,372,226-A1	04-16-2002	Aoki et al.	
	A9	US-6,432,404	08-13-2002	Gallatin et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	B1	WO 93/11236	06-10-1993	Medical Research Council	
	B2	WO 93/21259	10-28-1993	Cornell Research Foundation Inc.	
	B3	WO 99/10494	03-04-1999	Genentech, Inc.	
	B4	WO 00/24782	05-04-2000	Amgen, Inc.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). <sup>2</sup> See Kind's Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C1	Allen et al., <i>J. Comp. Neurol.</i> , Vol. 350, pp.357-366 (1994).		
	C2	Arfors et al., <i>Blood</i> , Vol. 69, pp.338-340 (1987).		
	C3	Amaout, <i>Blood</i> , Vol. 75, pp.1037-1050 (1990).		
	C4	Bardin et al., <i>Eur. J. Pharmacol.</i> , Vol. 409, pp.37-43 (2000).		
	C5	Basso et al., <i>J. Neurotrauma</i> , Vol. 12, pp.1-21 (1995).		
	C6	Bennett, <i>Pain</i> , Vol. 92, pp.147-157 (2001).		
	C7	Bevilacqua et al., <i>Ann. Rev. Immunol.</i> , Vol. 11, pp.7670-7804 (1993).		
	C8	Blight, <i>Central Nervous System Trauma</i> , Vol. 2, pp.299-315 (1985).		
	C9	Blight, <i>Neuroscience</i> , Vol. 60, pp.263-273 (1994).		
	C10	Bolhuis et al., <i>Cancer Immunol. Immunother.</i> , Vol. 34, pp.1-8 (1991).		
	C11	Bracken, <i>Spine</i> , Vol. 26, Supp. 24, pp.S47-S54 (2001).		
	C12	Bruce et al., <i>Exp. Neurol.</i> , Vol. 178, pp.33-48 (2002).		
	C13	Calejesan et al., <i>Brain Res.</i> , Vol. 798, pp.46-54 (1998).		
	C14	Carter et al., <i>J. Hematotherapy</i> , Vol. 4, pp.463-470 (1995).		
Examiner Signature			Date Considered	

940780

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/578,562-Conf. #7896
				Filing Date	May 8, 2006
				First Named Inventor	Lynne C. Weaver
				Art Unit	Not Yet Assigned 1649
				Examiner Name	K. Ballard
Sheet	2	of	3	Attorney Docket Number	27866/39702A

C15	Cobbold et al., <i>Leukocyte Typing III</i> , McMichael (Ed.), pp.788 (1987).	
C16	Corbi et al., <i>EMBO J.</i> , Vol. 6, pp.4023-4028 (1987).	
C17	Corbi et al., <i>J. Biol. Chem.</i> , Vol. 263, pp.12403-12411 (1988).	
C18	Coulthard et al., <i>J. Neurosci. Methods</i> , Vol. 128, pp.95-102 (2003).	
C19	Dall'Acqua et al., <i>Curr. Opin. Struct. Biol.</i> , Vol. 8, pp.443-450 (1998).	
C20	Danilenko et al., <i>J. Immunol.</i> , Vol. 155, pp.35-44 (1995).	
C21	Dedman et al., <i>J. Biol. Chem.</i> , Vol. 268, pp.23025-23030 (1993).	
C22	Fehlings et al., <i>Exp. Neurol.</i> , Vol. 132, pp.220-228 (1995).	
C23	Grayson et al., <i>Int. Arch. Allergy Immunol.</i> , Vol. 118, pp.263-264 (1999).	
C24	Grayson et al., <i>J. Exp. Med.</i> , Vol. 188, pp.2187-2191 (1998).	
C25	Greve et al., <i>Cell</i> , Vol. 56, pp.839-847 (1989).	
C26	Gris et al., <i>J. Neurosci.</i> , Vol. 24, pp.4043-4051 (2004).	
C27	Hains et al., <i>Exp. Neurol.</i> , Vol. 175, pp.347-362 (2002).	
C28	Hamon et al., <i>Novel Aspects of Pain Management: Opioids and Beyond</i> , Sawynok et al. Ed., pp. 203-228 (1999).	
C29	Hauben et al., <i>Lancet</i> , Vol. 355, pp.286-287 (2000).	
C30	Hildreth et al., <i>Science</i> , Vol. 244, pp.1075-1078 (1989).	
C31	Holliger et al., <i>Curr. Opin. Biotechnol.</i> , Vol. 4, pp.446-449 (1993).	
C32	Hurlbert, <i>Spine</i> , Vol. 26, pp.539-546 (2001).	
C33	Inman et al., <i>J. Comp. Neurol.</i> , Vol. 462, pp.431-449 (2003).	
C34	Jacobs et al., <i>Brain Res. Rev.</i> , Vol. 40, pp.45-52 (2002).	
C35	Jones et al., <i>J. Neurosci.</i> , Vol. 22, pp.2690-2700 (2002).	
C36	Jones et al., <i>Nature</i> , Vol. 321, pp.522-525 (1986).	
C37	Joshi et al., <i>J. Neurotrauma</i> , Vol. 19, pp.191-203 (2002).	
C38	Kishimoto et al., <i>Cell</i> , Vol. 48, pp.681-690 (1987).	
C39	Kortt et al., <i>Biomol. Eng.</i> , Vol. 18, pp.95-108 (2001).	
C40	Kunkel-Bagden et al., <i>Exp. Neurol.</i> , Vol. 119, pp.153-164 (1993).	
C41	Larson et al., <i>Immunol. Rev.</i> , Vol. 114, pp.181-217 (1990).	
C42	Larson et al., <i>J. Cell. Biol.</i> , Vol. 108, pp.703-712 (1989).	
C43	Letvin et al., <i>Blood</i> , Vol. 61, pp.408-410 (1983).	
C44	Mabon et al., <i>Exp. Neurol.</i> , Vol. 166, pp.52-64 (2000).	
C45	Marks et al., <i>J. Mol. Biol.</i> , Vol. 222, pp.581-597 (1991).	
C46	Means et al., <i>J. Neuropathol. &amp; Exp. Neurol.</i> , Vol. 42, pp.707-719 (1983).	
C47	Meller et al., <i>Neuropharmacol.</i> , Vol. 33, pp.1471-1478 (1994).	
C48	Miranti et al., <i>Natl. Cell Biol.</i> , Vol. 4, pp.E83-E90 (2002).	
C49	Moore et al., <i>Tissue Antigens</i> , Vol. 36, pp.211-220 (1990).	
C50	Morrison et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 81, pp.6851-6855 (1984).	
C51	Neuberger et al., <i>Nature</i> , Vol. 312, pp.604-608 (1984).	
C52	Nourshargh et al., <i>J. Immunol.</i> , Vol. 142, pp.3193-3198 (1989).	
C53	Oatway et al., <i>Pain</i> , Vol. 110, pp.259-268 (2004).	
C54	Ouweland et al., <i>Vox Sang.</i> , Vol. 71, Supp. 2, pp.223-232 (1998).	
C55	Owens et al., <i>J. Immunol. Meth.</i> , Vol. 168, pp.149-165 (1994).	
C56	Page et al., <i>J. Med. Lab. Tech.</i> , Vol. 22, pp.224 (1965).	
C57	Patarroyo et al., <i>Immunol. Rev.</i> , Vol. 114, pp.67-108 (1990).	
C58	Petty et al., <i>Immunol. Res.</i> , Vol. 25, pp.75-95 (2002).	

Examiner Signature 940780	Date Considered
------------------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/578,562-Conf. #7896
				Filing Date	May 8, 2006
				First Named Inventor	Lynne C. Weaver
				Art Unit	<del>Not Yet Assigned</del> 1649
				Examiner Name	K. Ballard
Sheet	3	of	3	Attorney Docket Number	27866/39702A

C59	Pluckthun et al., <i>Immunotechnology</i> , Vol. 3, pp.83-105 (1997).	
C60	Polistina et al., <i>J. Comp. Neurol.</i> , Vol. 299, pp.349-363 (1990).	
C61	Price et al., <i>J. Immunol.</i> , Vol. 139, pp.4174-4177 (1987).	
C62	Rader et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 95, pp.8910-8915 (1998).	
C63	Renner et al., <i>Immunological Reviews</i> , Vol. 145, pp.179-209 (1995).	
C64	Ribotta et al., <i>J. Neurosci.</i> , Vol. 20, pp.514-5152 (2000).	
C65	Riechmann et al., <i>Nature</i> , Vol. 332, pp.323-327 (1988).	
C66	Rivlin et al., <i>J. Neurosurg.</i> , Vol. 47, pp.577-581 (1977).	
C67	Sarhashi et al., <i>Exp. Neurol.</i> , Vol. 139, pp.203-213 (1996).	
C68	Saville et al., <i>J. Neuroimmunology</i> , Vol. 156, pp.42-57 (2004).	
C69	Schwartz et al., <i>J. Neuroimmunol.</i> , Vol. 113, pp.185-192 (2001).	
C70	Schwartz et al., <i>Natl. Cell Biol.</i> , Vol. 4, pp.E65-E68 (2002).	
C71	Segal et al., <i>Immunobiology</i> , Vol. 185, pp.390-402 (1992).	
C72	Segal et al., <i>J. Hematotherapy</i> , Vol. 4, pp.377-382 (1995).	
C73	Siddall et al., <i>Spinal Cord</i> , Vol. 39, pp.63-73 (2001).	
C74	Smith et al., <i>J. Clin. Invest.</i> , Vol. 83, pp.2008-2017 (1989).	
C75	Springer, <i>Nature</i> , Vol. 346, pp.425-434 (1990).	
C76	Takagi et al., <i>Immunol Rev.</i> , Vol. 186, pp.141-163 (2002).	
C77	Takeda et al., <i>Nature</i> , Vol. 314, pp.452-454 (1985).	
C78	Tasker, <i>The Management of Pain</i> , Bonica JJ Ed., pp.264-283 (1990).	
C79	Todorovska et al., <i>J. Immunol. Methods</i> , Vol. 248, pp.47-56 (2001).	
C80	Trowbridge et al., <i>J. Exp. Med.</i> , Vol. 154, pp.1517-1524 (1981).	
C81	van der Flier et al., <i>Cell Tissue Res.</i> , Vol. 305, pp.285-298 (2001).	
C82	Van der Vieren et al., <i>Immunity</i> , Vol. 3, pp.683-690 (1995).	
C83	Verhoeven et al., <i>Science</i> , Vol. 239, pp.1534-1536 (1988).	
C84	Vierck et al., <i>Pain</i> , Vol. 89, pp.1-5 (2000).	
C85	Weaver et al., <i>J. Neurotrauma</i> , Vol. 18, pp.1107-1119 (2001).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 940789	/Kimberly Ballard/	Date Considered	03/19/2009
---------------------------------	--------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./



Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Project (03-10-39702A) persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/578,562

Attorney Docket No.: 27866/39702A

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on December 28, 2006  
Date

Signature

Katherine L. Neville

Typed or printed name of person signing Certificate

53,379  
Registration Number, if applicable

(312) 474-6632  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (98 References) (3 pages)